Nissha (7915) FY2026 Q1 Earnings Report

Quick View

Executive Summary

In Q1, a decline in revenue and a substantial decrease in operating income occurred simultaneously, with deteriorating profitability being the primary feature. Revenue amounted to ¥457.9B (-3.5% YoY), while operating income was limited to ¥7.5B (-47.6% YoY). In contrast, net income attributable to owners of the parent increased substantially to ¥4.2B from ¥0.1B in the same period of the previous year. The decline in operating income was primarily attributable to the downturn in the Devices Business and an increase in the SG&A ratio, while the increase in net income resulted from improved financial income and expenses and higher profit before tax, representing a divergence driven by factors separate from operating results.

Factors Affecting Performance

【Revenue】Revenue decreased 3.5% YoY to ¥457.9B. By segment, Devices declined substantially to ¥104.0B (-23.3% YoY), offsetting revenue increases in Industrial Materials of ¥195.3B (+4.0% YoY) and Medical of ¥141.3B (+3.7% YoY). The primary reason for the company-wide revenue decline was weakening demand in the Devices Business.

【Profit and Loss】Operating income was ¥7.5B (¥14.3B in the same period of the previous year, -47.6% YoY), and the operating margin declined to 1.6% from 3.0% in the same period of the previous year, a decrease of approximately 1.4pt. Although the gross margin declined slightly to 24.1% from 24.4% in the same period of the previous year, the more significant factor was the increase in SG&A expenses. SG&A expenses increased to ¥100.2B (+2.8% YoY), and the SG&A ratio rose to 21.9% from 21.6% in the same period of the previous year, amplifying the decline in operating income through a higher fixed-cost burden during a period of decreasing revenue. By segment, Medical secured an increase in operating income to ¥8.4B (+13.3% YoY), while Industrial Materials at ¥7.1B (-30.0% YoY) and Devices at ¥3.9B (-54.7% YoY) recorded declines, weighing on company-wide profit. While operating income declined substantially, financial income of ¥4.6B and financial expenses of ¥4.6B nearly offset each other, resulting in profit before tax of ¥7.5B, up +26.8% YoY. After deducting income taxes of ¥3.0B (effective tax rate of 40.3%), net income was ¥4.5B (¥1.0B in the same period of the previous year), while net income attributable to owners of the parent was ¥4.2B (¥0.1B in the same period of the previous year). The differing directions of operating income and net income were attributable to the reversal of the heavy financial expenses recorded in the same period of the previous year. In conclusion, the current period represented a decline in revenue and operating-based profit, while the improvement in net income was driven by non-operating factors.

Segment Analysis

The reporting segments comprise Industrial Materials, Devices, and Medical. Industrial Materials recorded revenue of ¥195.3B (+4.0%) but a decline in operating income to ¥7.1B (-30.0%), with its margin falling to 3.6%. Devices experienced the largest decline, with revenue of ¥104.0B (-23.3%) and operating income of ¥3.9B (-54.7%), resulting in a margin of 3.8%. Medical was the only segment to achieve both revenue and operating income growth, recording revenue of ¥141.3B (+3.7%), operating income of ¥8.4B (+13.3%), and a margin of 6.0%, the highest level among the three segments, thereby supporting company-wide profit. Company-wide adjustments deteriorated to -¥12.9B from -¥10.2B in the same period of the previous year, creating a structure in which improvements in segment profit are less likely to be reflected in consolidated operating income.

Key Financial Indicators

【Profitability】The 1.6% operating margin declined from 3.0% in the same period of the previous year, while the net profit margin remained limited to 1.0%. ROE was low at 0.4%, indicating challenges in terms of capital efficiency.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥39.7B, substantially exceeding net income attributable to owners of the parent of ¥4.2B, indicating favorable cash conversion of earnings. However, the primary factor was a ¥31.5B decrease in trade receivables, while inventories increased by ¥33.2B; consequently, attention is required regarding sustainability from a working capital perspective.【Investment Efficiency】Against capital expenditures of ¥13.8B, OCF was secured at ¥39.7B, maintaining positive free cash flow of ¥24.1B.【Financial Soundness】The equity ratio was 46.5%, nearly unchanged from 46.1% in the same period of the previous year. Interest-bearing debt (bonds and borrowings) comprised current liabilities of ¥326.1B and non-current liabilities of ¥288.6B, totaling ¥614.7B. After deducting cash and cash equivalents of ¥387.2B, net interest-bearing debt was ¥227.5B. While short-term borrowings were repaid during Q1, bonds were issued, indicating progress toward extending the maturity of funding.

Cash Flow Analysis

OCF was positive at ¥39.7B, a substantial improvement from -¥10.9B in the same period of the previous year. The primary driver of the improvement was a ¥31.5B decrease in trade receivables. This was based on a subtotal of ¥46.9B, including profit before tax of ¥7.5B and depreciation and amortization of ¥25.6B, while a ¥33.2B increase in inventories partially offset cash generation. Investing Cash Flow was -¥15.6B, primarily comprising ¥13.8B for the acquisition of property, plant and equipment and ¥2.0B for the acquisition of intangible assets. Free cash flow, calculated as OCF plus investing cash flow, remained positive at ¥24.1B. Financing Cash Flow was -¥35.4B, with repayment of short-term borrowings of ¥65.0B and bond issuance of ¥54.7B largely offsetting each other, indicating an extension of the funding structure. In addition, dividend payments to the parent company’s shareholders of ¥11.8B and lease payments of ¥6.0B were negative factors for financing cash flow. Cash and cash equivalents stood at ¥387.2B at period-end, a decrease of ¥4.9B from the beginning of the period, although a foreign currency translation gain of ¥6.4B partially offset the decline.

Earnings Quality

Operating income of ¥7.5B includes other income of ¥2.2B, other expenses of ¥4.0B, and equity-method investment losses of ¥1.0B, resulting in a limited net impact from these non-operating items. Financial income of ¥4.6B and financial expenses of ¥4.6B nearly offset each other, leaving profit before tax of ¥7.5B at approximately the same level as operating income. Gains and losses on disposal of fixed assets were negligible at ¥0.01B, and no temporary factors with a substantial impact on net income were identified within the disclosed scope. The fact that OCF substantially exceeded net income attributable to owners of the parent is favorable from a cash conversion perspective; however, the primary driver was the collection of trade receivables, while inventories also increased. Accordingly, inventory consumption trends should be monitored with respect to the sustainability of cash generation. Comprehensive income of ¥22.6B includes foreign currency translation adjustments of ¥13.3B and fair value changes in financial assets of ¥4.4B. The divergence from net income of ¥4.2B was primarily attributable to foreign exchange and market factors and should be distinguished from an improvement in underlying business earnings.

Earnings Forecast and Guidance

Q1 progress against the full-year forecast was 23.1% for revenue (¥457.9B / ¥1,980.0B), 10.7% for operating income (¥7.5B / ¥70.0B), and 13.2% for net income attributable to owners of the parent (¥4.2B / ¥32.0B). Revenue progress remained slightly below the simple proportional benchmark of 25%, while progress for operating income and net income was substantially lower. The company expects significant full-year improvements of +1.6% in revenue, +73.3% in operating income, and +219.4% in net income. Based on progress during the current quarter, this indicates that substantial improvement in profitability during the second half is a prerequisite. The company revised its earnings forecast during the current quarter.

Shareholder Returns

Dividend payments during Q1 were ¥11.8B, which represents a high level on a simple comparison with net income attributable to owners of the parent of ¥4.2B. However, as the timing of quarterly dividend payments does not coincide with the timing of earnings recognition, it is not appropriate to evaluate shareholder returns based solely on this ratio. Based on the full-year forecast of a dividend per share of ¥50.00, forecast net income attributable to owners of the parent of ¥32.0B, and weighted-average shares outstanding during the period of 47,397,742 shares, the forecast total dividend amount is approximately ¥23.7B and the forecast payout ratio is approximately 74%. There was no revision to the dividend forecast during the current quarter. Share repurchases were virtually nonexistent, and shareholder returns during the current quarter consisted solely of dividends. Free cash flow of ¥24.1B was sufficient to cover dividend payments during the current quarter, confirming support from cash generation.

Risk Factors

1. Declining demand in the Devices Business: Revenue deteriorated substantially by -23.3% YoY, while operating income declined by -54.7%. Recovery in this business will be an important factor in achieving the full-year plan.

2. Working capital fluctuations: Inventories increased by +¥36.1B (+11.3%) from the end of the previous fiscal year, and annualized inventory turnover days are trending upward. If the demand outlook deteriorates, impacts on inventory valuation and capital efficiency may arise.

3. Goodwill level: Goodwill was ¥339.3B, accounting for 28.6% of net assets. Under IFRS, goodwill is not subject to regular amortization; therefore, the possibility of impairment must be continuously monitored if the profitability of acquired businesses falls below plan.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both of the company’s profitability indicators are substantially below the industry median and rank toward the lower end of the industry.

Growth and Capital Efficiency

The revenue growth rate is also substantially below the industry median, contrasting with peers that are experiencing revenue growth.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The Medical Business maintained both revenue and operating income growth (revenue +3.7%, operating income +13.3%) and served as a support for company-wide earnings as the largest contributor to profit among the reporting segments. This is noteworthy for understanding the structure of the business portfolio.

2. The operating margin declined to 1.6%, with the increase in SG&A expenses becoming a factor weighing on profit during a period of declining revenue. Q1 progress against the full-year operating income plan was limited to 10.7%, making the extent to which profitability improves during the second half a key focus going forward.

3. OCF substantially exceeded net income and free cash flow remained positive. However, the simultaneous collection of trade receivables and increase in inventories require close monitoring of the qualitative composition of working capital.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,966–¥2,076 at ±1% for the cost of equity, and ¥2,006–¥2,029 at ±0.1 for ω.

Notes:

• Net income is substantially compressed relative to operating income due to tax burden, acquisition-related expenses, non-controlling interests, and other factors (net income ÷ operating income 46%). This value reflects that compression at face value; if the factors are temporary, underlying earning power may be higher.
• As forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual income model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

NISSHA’s FY2026 Q1 result was operationally weak, with lower sales and a sharp contraction in operating profit, although profit attributable to owners recovered from an exceptionally low prior-year base. Revenue declined 3.5% YoY to ¥45.79bn. Operating income fell 47.6% YoY to ¥0.75bn, leaving the operating margin at 1.6%, down 140bp from 3.0% in FY2025 Q1. Gross profit decreased ¥0.52bn to ¥11.05bn, but the gross margin remained broadly stable at 24.1%, versus 24.4% a year earlier, a modest 30bp compression. The larger earnings pressure came below gross profit, as SG&A increased 2.8% YoY to ¥10.02bn despite the sales decline. This negative operating leverage reduced operating income by ¥0.68bn. Industrial Materials and Devices both experienced lower segment profit, while Medical delivered higher revenue and profit. The Medical segment was the largest contributor to reported segment profit at ¥0.84bn and generated the highest segment margin at approximately 6.0%. Consolidated operating income was additionally constrained by unallocated corporate costs and foreign-exchange-related items of ¥1.29bn, compared with ¥1.02bn a year earlier. Finance income of ¥0.46bn almost fully offset finance costs of ¥0.46bn, resulting in profit before tax of ¥0.75bn, slightly above operating income. Net income was ¥0.45bn, while profit attributable to owners was ¥0.42bn, substantially above the ¥0.01bn owner-attributable profit recorded in the prior-year quarter. The improvement in owner-attributable income therefore reflects an unusually low comparison base and lower finance costs rather than an improvement in core operating performance. Operating cash flow was strong at ¥3.97bn and free cash flow was ¥2.41bn, exceeding reported net income. Cash conversion was supported principally by a ¥3.15bn reduction in receivables, partly offset by a ¥3.32bn inventory build. The balance sheet remains adequately capitalized, with a 46.5% equity ratio, a 1.52x current ratio, and a 1.05x quick ratio. However, annualized ROE of 1.4%, ROIC of 1.5%, a 1.6% EBIT margin, receivable days of 73, and inventory days of 93 indicate weak capital and working-capital efficiency. Full-year guidance implies a substantial second-half-oriented recovery: Q1 operating-profit progress is only 10.7% against a standard 25% quarterly pace. The key forward issue is whether the Medical segment’s growth and a recovery in Devices can offset elevated corporate costs, low manufacturing utilization, and working-capital intensity sufficiently to achieve the full-year operating-income target.

Profitability Analysis

The reported annualized DuPont ROE is 1.4%, decomposed into a 0.9% net profit margin, 0.727x annualized asset turnover, and 2.13x financial leverage. The primary constraint on shareholder returns is the very low net margin rather than insufficient leverage. EBIT margin was only 1.6%, below the 5% level generally associated with acceptable operating efficiency, and declined from approximately 3.0% in the prior-year quarter. Gross margin was comparatively resilient at 24.1%, declining only around 30bp YoY, indicating that the major deterioration occurred in operating expenses and segment/corporate cost absorption rather than direct production cost alone. SG&A rose 2.8% YoY while revenue fell 3.5%, demonstrating adverse operating leverage and absorbing nearly 91% of gross profit. Industrial Materials revenue increased 4.0% YoY to ¥19.53bn, but segment profit declined 30.0% to ¥0.71bn; its segment margin fell 176bp to 3.6%. Devices revenue decreased 23.3% YoY to ¥10.40bn and segment profit fell 54.7% to ¥0.39bn; its margin compressed 261bp to 3.8%, making this the largest reported segment-level deterioration. Medical revenue increased 3.7% to ¥14.13bn and segment profit increased 13.3% to ¥0.84bn, lifting its margin 50bp to 6.0%. Medical is therefore the core business in Q1 based on its ¥0.84bn operating-income contribution, ahead of Industrial Materials at ¥0.71bn and Devices at ¥0.39bn. Other businesses produced ¥0.10bn of segment profit, compared with a ¥0.17bn loss a year earlier. Unallocated corporate expenses increased ¥0.27bn to ¥1.29bn, reducing the benefit of segment-level profitability. The tax burden was 0.562, equivalent to an effective tax rate of 40.3%, which is elevated versus the normal benchmark and reduced the conversion of pre-tax income into net income. The near-neutral interest burden of 1.001 reflects finance income broadly offsetting finance costs, so financing costs were not the principal reason for weak Q1 profitability. The ROIC quality alert is material: ROIC of 1.5% is well below 5%, indicating that returns on the company’s operating asset base and acquired intangible assets remain inadequate. Given goodwill of ¥33.93bn and intangible assets of ¥23.08bn, sustained margin recovery is necessary for capital efficiency to improve.

Growth Assessment

Revenue growth was negative in Q1, with consolidated sales down 3.5% YoY, led by the 23.3% contraction in Devices. Industrial Materials grew 4.0% YoY and Medical grew 3.7%, providing partial offsets to the Devices decline. The segment mix is becoming more dependent on Medical, whose Q1 segment margin of 6.0% exceeded the group operating margin materially. Medical’s business model includes medical-device and pharmaceutical CDMO activities, which may offer relatively recurring demand characteristics, but its current growth rate alone is insufficient to offset the scale of the Devices sales decline. Industrial Materials maintained revenue momentum but experienced profit-margin compression, implying that sales growth has not yet translated into operating leverage. The full-year revenue forecast is ¥198.0bn, implying 1.6% YoY growth; Q1 revenue progress is 23.1%, modestly below the standard 25% pace but not in itself a major deviation. Full-year operating-income guidance is ¥7.0bn, implying 73.3% YoY growth; Q1 progress is only 10.7%, 14.3 percentage points below the standard 25% pace. Full-year profit attributable to owners guidance is ¥3.2bn, and Q1 progress is 13.2%, also below the standard quarterly pace by 11.8 percentage points. Thus, management’s revised forecast requires a pronounced acceleration in operating profit over the remaining nine months, not merely revenue growth. The recovery path depends on Devices demand normalization, Industrial Materials margin restoration, and containment of corporate and foreign-exchange-related costs. Finance income and costs were nearly offset in Q1, so the forecast’s earnings recovery must be driven predominantly by operating improvement. The inventory increase of ¥3.32bn in Q1 should be monitored against subsequent sales, as successful conversion into revenue would support the forecast while continued accumulation would indicate weaker demand or production-demand mismatch.

Financial Health

Financial health is adequate but leverage and asset composition require monitoring. Current assets were ¥116.76bn against current liabilities of ¥77.02bn, producing a current ratio of 1.52x, above the 1.0x warning threshold and consistent with satisfactory short-term liquidity. Excluding inventories, the quick ratio was approximately 1.05x, indicating that liquid assets and receivables broadly cover current liabilities. Cash and cash equivalents were ¥38.72bn, equivalent to approximately half of current liabilities. Total bonds and borrowings were ¥61.47bn, consisting of ¥32.61bn current and ¥28.86bn non-current. Lease liabilities totaled ¥11.22bn, comprising ¥2.32bn current and ¥8.90bn non-current, and represent a material fixed contractual obligation alongside debt. The reported debt-to-equity ratio of 1.13x is above the conservative 1.0x benchmark but well below the 2.0x aggressive-leverage warning threshold. Short-term bonds and borrowings declined ¥6.17bn from fiscal year-end, while non-current bonds and borrowings increased ¥5.15bn, reflecting a refinancing shift toward longer maturities. This reduces near-term refinancing pressure, although current debt of ¥32.61bn remains meaningful relative to cash of ¥38.72bn. Working capital was positive at ¥39.73bn, calculated as current assets less current liabilities. Equity increased to ¥118.54bn from ¥117.87bn at fiscal year-end, and the equity ratio improved to 46.5% from 46.1%. Goodwill represented 28.6% of equity and 13.5% of total assets, remaining just below the 30% goodwill-to-equity elevated-risk threshold. Intangible assets represented 9.2% of total assets, a manageable level under IFRS. The company uses IFRS, under which goodwill is not amortized and is instead subject to impairment testing; therefore, the ¥33.93bn goodwill balance requires continued validation through acquisition performance and cash-generating-unit profitability. Defined-benefit obligations of ¥5.33bn and lease liabilities are additional long-term obligations relevant to fixed-charge resilience.

Notable B/S Changes

Non-current bonds and borrowings: +¥5.15bn (+21.7%) from FY2025 year-end to ¥28.86bn — refinancing shifted part of the funding structure toward longer maturities, reducing immediate maturity concentration. Current bonds and borrowings: -¥6.17bn (-15.9%) from FY2025 year-end to ¥32.61bn — short-term debt reduction supports near-term liquidity, partly funded by ¥5.47bn of bond issuance. Non-controlling interests: -¥10.53bn (-41.2%) from FY2025 year-end to ¥1.50bn — reflects transactions involving subsidiary ownership interests and materially changes the allocation of subsidiary equity. Current provisions: +¥5.16bn (+285.1%) from FY2025 year-end to ¥6.97bn — a substantial increase requiring monitoring for its underlying operational or contractual drivers. Inventories: +¥3.61bn (+11.3%) from FY2025 year-end to ¥35.50bn — the absolute increase is material in the context of Q1 sales and is consistent with the elevated 93-day annualized inventory cycle. Accounts receivable: -¥2.82bn (-7.1%) from FY2025 year-end to ¥36.61bn — supported Q1 operating cash flow, although annualized DSO remains elevated at 73 days.

Cash Flow Quality

Cash-flow quality was strong in Q1 on a reported basis. Operating cash flow was ¥3.97bn, equal to 9.41x net income of ¥0.42bn on the reported metric, well above the 0.8x earnings-quality warning threshold. The accruals ratio was negative 1.4%, which is consistent with favorable cash conversion rather than aggressive accrual-based earnings recognition. Operating cash flow was supported by non-cash depreciation and amortization of ¥2.56bn and a ¥3.15bn reduction in receivables. However, this favorable receivables movement was partly offset by a ¥3.32bn inventory increase. The inventory build is the principal working-capital risk: annualized inventory days were 93, exceeding both the 90-day warning level and the 60-day manufacturing-efficiency benchmark. Annualized receivable days were also elevated at 73 days, above the 60-day warning threshold and indicating a comparatively long collection cycle. The combination of high DSO and DIO indicates that a meaningful share of capital is tied up in the order-to-cash cycle, even though Q1 receivables declined. Payables increased ¥0.55bn, which modestly supported operating cash flow but was not the main driver. Free cash flow was ¥2.41bn after ¥1.38bn of capital expenditures. Q1 capital expenditure was 3.0% of revenue, at the low end of the typical manufacturing range, while the available data does not permit a capex-to-depreciation assessment. Investing outflow was contained at ¥1.56bn, compared with ¥7.60bn in the prior-year quarter, when subsidiary acquisition spending was significant. Financing cash flow was negative ¥3.54bn, primarily reflecting net short-term debt repayment, lease payments, dividends, and a partial offset from ¥5.47bn of bond issuance. Cash declined only ¥0.49bn during the quarter, with a favorable ¥0.64bn foreign-exchange translation effect on cash. The main issue is not current cash generation, but whether inventory accumulation is converted to sales and cash in subsequent quarters rather than becoming a drag on future operating cash flow or requiring inventory provisions.

Dividend Sustainability

The full-year dividend forecast is ¥50.00 per share, unchanged according to the disclosed dividend revision status. Based on forecast EPS of ¥67.49, the forecast dividend payout ratio is approximately 74.1%. This is above the 60% sustainability benchmark, so dividend coverage depends on management achieving its earnings forecast and maintaining strong cash conversion. Q1 cash dividends paid to owners were ¥1.18bn. Q1 free cash flow of ¥2.41bn covered these cash dividends by approximately 2.0x, providing near-term cash-flow support for distributions. In contrast, Q1 profit attributable to owners of ¥0.42bn covered the cash dividend payment by only approximately 0.36x. This mismatch is not necessarily indicative of an immediate problem because the payment may relate to the prior fiscal year and quarterly earnings are seasonal, but it underscores reliance on a substantial earnings recovery later in FY2026. No material share repurchases were recorded in Q1, so the analysis is appropriately focused on the dividend payout ratio rather than a total return ratio. The balance sheet and Q1 free cash flow provide capacity for the current distribution, but the elevated forecast payout ratio leaves less room for operational underperformance, working-capital outflows, or incremental investment needs. Dividend sustainability should therefore be assessed primarily against delivery of the ¥3.2bn full-year owner-attributable profit forecast and normalization of inventory cash conversion.

Risk Assessment

Business risks include High priority — Devices revenue fell 23.3% YoY to ¥10.40bn and segment profit fell 54.7% to ¥0.39bn. A prolonged downturn in touch-sensor, gas-sensor, or related device demand would challenge the required full-year earnings recovery., High priority — Consolidated operating margin was only 1.6%, while SG&A increased 2.8% despite declining revenue. This low margin leaves earnings highly sensitive to modest volume, pricing, product-mix, and utilization changes., High priority — Inventory days of 93 exceed the 90-day warning threshold. For a manufacturer, sustained excess inventory raises risks of demand misalignment, lower factory utilization, discounting, obsolescence, and future write-downs., Medium priority — Receivable days of 73 exceed the 60-day warning threshold. The longer collection cycle increases working-capital intensity and can expose cash flow to customer payment delays., Medium priority — Industrial Materials revenue grew but its segment margin declined from 5.4% to 3.6%. Raw-material, energy, yield, pricing, and product-mix pressures could inhibit conversion of volume growth into earnings., Medium priority — Medical is the strongest reported segment, but its performance is exposed to CDMO customer concentration, regulatory compliance, product quality, and manufacturing validation requirements., Medium priority — Foreign-currency movements affect unallocated corporate costs and overseas operations. Translation gains contributed ¥1.33bn to OCI in Q1, illustrating meaningful overseas-exposure sensitivity..

Financial risks include Medium priority — The reported debt-to-equity ratio is 1.13x, above the conservative 1.0x benchmark, while total borrowings are ¥61.47bn and lease liabilities are ¥11.22bn. Although not aggressive, leverage limits flexibility if profitability remains subdued., Medium priority — Current bonds and borrowings of ¥32.61bn are sizable relative to cash of ¥38.72bn. The Q1 shift from short-term to long-term funding improved maturity structure, but access to refinancing markets remains important., Medium priority — Goodwill is ¥33.93bn, equal to 28.6% of equity. It is below the elevated-risk threshold but remains material under IFRS because future underperformance of acquired businesses could trigger impairment charges., Medium priority — The effective tax rate was 40.3% and tax burden was 0.562, below the 0.60 warning benchmark. A persistently high tax burden would constrain net-income recovery even if operating profit improves., Low to medium priority — Annualized ROE of 1.4% and ROIC of 1.5% are materially below acceptable return thresholds, increasing the risk that capital deployment and acquisitions do not create adequate shareholder value..

Key concerns include The most immediate investment-monitoring issue is the gap between Q1 operating-profit progress of 10.7% and the standard 25% pace implied by full-year guidance., The earnings thesis requires margin recovery, because the full-year operating-income forecast of ¥7.0bn cannot be achieved through the current 1.6% operating-margin run rate., Cash flow was strong in Q1, but it was supported by receivable collection while inventory rose ¥3.32bn; subsequent inventory conversion is essential., The Quality Alerts are directionally consistent: low operating efficiency, low ROIC, high tax burden, high receivable days, and high inventory days each weaken the quality and sustainability of the anticipated earnings recovery., Manufacturing-specific exposures include material and energy-cost volatility, foreign-exchange fluctuations, utilization risk in Devices, supply-chain disruption, customer demand cyclicality, and quality or regulatory events in Medical operations..

Investment Implications

Key takeaways include Q1 core operating performance weakened: revenue declined 3.5% and operating income declined 47.6%, with operating margin falling to 1.6%., Medical was the Q1 core business by segment operating-income contribution, producing ¥0.84bn of profit on ¥14.13bn of revenue and a 6.0% margin., Devices was the major drag, with revenue down 23.3% and segment profit down 54.7% YoY., Q1 operating cash flow of ¥3.97bn and free cash flow of ¥2.41bn were strong relative to net income, but inventory accumulation remains a material cash-conversion risk., The balance sheet is liquid enough for near-term obligations, with a 1.52x current ratio, 1.05x quick ratio, and 46.5% equity ratio., The full-year forecast embeds a significant back-end recovery, with Q1 operating-income progress at 10.7% versus a standard 25% pace., Goodwill exposure is material but currently contained, at 28.6% of equity and 13.5% of assets..

Metrics to watch include Devices quarterly sales growth, segment margin, and customer-demand recovery, Medical segment revenue growth and maintenance of its approximately 6% segment margin, Consolidated SG&A growth relative to revenue growth and the level of unallocated corporate costs, Operating-margin progression toward the level needed to support ¥7.0bn full-year operating income, Annualized receivable days, inventory days, and the conversion of the ¥3.32bn Q1 inventory build into sales and operating cash flow, Operating cash flow and free cash flow after dividends, capital expenditures, and lease payments, Borrowing maturity profile, net debt movement, and finance-cost coverage, Goodwill carrying value and any impairment indicators in acquired Medical or other businesses, Effective tax rate and the tax burden's effect on conversion of operating profit to owner-attributable income.

Regarding relative positioning, NISSHA’s Q1 profile is that of a diversified manufacturing and medical-CDMO group with a comparatively resilient Medical segment, but group profitability and capital efficiency are currently weak. Its 46.5% equity ratio, positive free cash flow, and goodwill-to-equity ratio below 30% are balance-sheet positives. Relative to efficient manufacturing benchmarks, however, the 1.6% operating margin, 1.5% ROIC, 73-day receivable cycle, and 93-day inventory cycle indicate below-par operating and working-capital performance. Delivery of the revised full-year forecast depends on a material improvement from the current run rate.